To include your compound in the COVID-19 Resource Center, submit it here.

Samsung Bioepis enters novel drug space via Takeda deal

Samsung Bioepis Co. Ltd. is expanding its focus beyond biosimilars to discover, develop and commercialize novel biologics. The company will start to build its novel pipeline via collaborations, including its first co-development deal with

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE